Omnicom Group Inc. (OMC) Competitors & Peers
The 5 largest companies in the same industry as Omnicom Group Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| APP | Peer | $313.55 | P/E 25.2RSI 48Cap 110.1 B |
| 6058.T | Peer | $1,992.00 | P/E 18.3RSI 55Cap 93.4 B |
| 6045.T | Peer | $2,090.00 | P/E 6.4RSI 51Cap 16.4 B |
| 6094.T | Peer | $523.00 | P/E 6.2RSI 35Cap 9.1 B |
| TTD | Supplier | $13.99 | P/E 16.9RSI 46Cap 6.7 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- BBDOCustomer
BBDO operates as a leading agency network subsidiary within Omnicom.
Model-inferred, unverified — treat as a lead, not evidence - IPGMerger
Omnicom announced $14B all-stock acquisition of Interpublic Group (Dec 2024).
Model-inferred, unverified — treat as a lead, not evidence - IPGPartner
Omnicom announced $14B all-stock acquisition of Interpublic (Dec 2024).
Model-inferred, unverified — treat as a lead, not evidence - TTDSupplier
Omnicom is largest single agency holdco trading on TTD DSP; opened Big Four audit Oct 2025.
Model-inferred, unverified — treat as a lead, not evidence - GOOGLSupplier
Omnicom is a top Google Ads agency partner globally.
Model-inferred, unverified — treat as a lead, not evidence - TTDSupplier
Omnicom is among the two agency holding companies representing ~30% of TTD platform spending in 2025; launched Big Four audit of TTD agreement Oct 2025.
Model-inferred, unverified — treat as a lead, not evidence - METASupplier
Omnicom is a top Meta Ads agency partner globally.
Model-inferred, unverified — treat as a lead, not evidence